Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients
11 Septiembre 2023 - 11:00AM
Daxor
Corporation (NASDAQ: DXR), the
global leader in blood volume measurement technology, today
announced that the National Institutes of Health (NIH) National
Institute of General Medical Sciences (NIGMS) has awarded the
Company a $305K Phase I Small Business Innovative Research (SBIR)
grant to support the development of the Sepsis FLO (Sepsis Fluid
Optimizer), a clinical decision support tool designed to precisely
guide blood volume management and treatment in sepsis patients.
“Sepsis impacts 1.7 million Americans annually,
leading to 270,000 deaths and $62 billion in costs,” said Michael
Feldschuh, CEO and President of Daxor Corporation. “There is a
significant unmet need for a rapid bedside test with a clinically
validated sepsis fluid guidance support tool based on precise,
objective assessment of circulating blood volume. Fluid management
guided by our 98% accurate blood volume diagnostic represents a
potential paradigm shift in clinical practice, which to date has
been based on surrogate markers that lack sensitivity and
specificity.”
“This award represents our seventh SBIR
grant/contract to support the continued development of our next
generation technologies,” commented Jonathan Feldschuh, Chief
Science Officer of Daxor. “The development of a clinical
decision-support system will help clinicians translate blood volume
analysis results into actionable treatment decisions.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the only diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 65,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing trials in the areas of
heart failure treatment with support from the NIH and is under
contract developing analyzers to improve combat casualty care with
the U.S. Department of Defense. Daxor's mission is to advance
healthcare by enabling optimal fluid management with blood volume
analysis. Daxor’s vision is optimal blood volume for all. For more
information, please visit our website at Daxor.com. Sign up to
receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR1-516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Daxor (NASDAQ:DXR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024